IP Australia has rejected the patent application of Scandinavian dairy giant Arla Foods amba, finding its high-protein whey-based yoghurt invention lacked an inventive step.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.
A judge has slammed Novartis for putting forward four “overlapping” experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a “hot tub”.
Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its “inherently implausible” opposition to the patent.
Melbourne-based joint venture Shepparton Partners Collective has lost its appeal of a $1.2 million judgment that found it infringed software developer QAD’s copyright by failing to pay a transfer fee to retain the licence after it acquired the iconic SPC Ardmona cannery in Victoria from Coca-Cola Amatil for $40 million.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.
Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.
IP Australia has refused to register a patent acquired by Elanco Australasia from Bayer covering a lice treatment, after amendments failed to address findings that the patent lacked an inventive step.